Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon

Scandinavian Journal of Rheumatology

Volumn 33, Issue 4, 2004, Pages 253-257

  Marasini, B ^a,d   Massarotti, M ^a   Bottasso, B ^b   Coppola, R ^b   Del Papa, N ^c   Maglione, W ^c   Comina, D P ^c   Maioli, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c G Pini Orthopaedic Institute   (Italy)

^d SAN PAOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROSTAGLANDIN E1; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINGER; FOLLOW UP; HEADACHE; HEMOCONCENTRATION; HUMAN; INJECTION SITE; LABORATORY; NAUSEA; PAIN; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCORING SYSTEM; SIDE EFFECT; SKIN; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ULCER; VOMITING;

EID: 4444357352     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740310004711     Document Type: Article

References (38)

1. McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47:43-7.
2. Yardumian DA, Isenberg DA, Rustin M, Belcher G, Snaith ML, Dowd PM, et al. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988;27:220-6.
3. Torley HI, Madhok R, Capell HA, Brouwer RM, Maddison PJ, Black CM, et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50:800-4.
4. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
5. Martin MF, Dowd PM, Ring EF, Cooke ED, Dieppe PA, Kirby JD. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis 1981;40:350-4.
6. Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome. Ann Rheum Dis 1985;44:754-60.
7. Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, et al. Treatment of Raynaud's phenomenon with intravenous ptostaglandin E1 alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 2001;28:786-94.
8. Belch JJ, Newman P, Drury JK, McKenzie F, Capell H, Leiberman P, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet 1983;1:313-5.
9. Bellucci S, Kedra AW, Courmelle JM, Maclouf J, Boizard B, Dosquet-Bernard C, et al. Prolonged remission in Raynaud's phenomenon after prostacyclin infusion. Scand J Rheumatol 1986;15:392-8.
10. Musial J, Wilczynska M, Sladek K, Cierniewski CS, Nizankowski R, Szczeklik A. Fibrinolyitc activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 1986;31:61-70.
11. Bertelè V, Mussoni L, Del Rosso G. Defective fibrinolytic response in atherosclerotic patients: effects of iloprost and its possible mechanism of action. Thromb Haemost 1988;60: 141-4.
12. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983;3:295-315.
13. Mittag M, Beckheinrich P, Haustein UF. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 2001;81: 294-7.
14. Kahaleh MB. Matucci Cerinic M, Fan P-S. Modulation of endothelial gene expression by prostanoids in systemic sclerosis. Arthritis Rheum 2000:43 (Suppl 9):S258.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association: diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). J Rheumatol 1980;23: 581-90.
16. Sharp GC, Irvin WS, May CM, Holman HR, McDuffie FC, Hess EV, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systemic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976;295:1149-54.
17. Mannucci PM, Coppola R. Von Willebrand factor. In: Jespersen J, Bertina RM, Haverkate F, editors. ECAT assays procedures. Laboratory techniques in thrombosis: a manual. Lancaster: Kluwer Academic Publishers UK, 1999. p.115.
18. Rodnan GP, Lipinski E, Luksicki J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22:130-40.
19. Stratton R, Shiwen X, Martin G. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108:241-50.
20. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, et al. Comparison of intravenous infusion of iloprost and oral nifedipine in treatment of Raynaud's phenomenon patients with systemic sclerosis: a double-blind randomized study. Br Med J 1989;298:561-4.
21. Kyle MV, Belcher G, Hazleman BL. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992;19:1403-6.
22. Fisher CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E on human platelet function. J Lab Clin Med 1987;109:184-90.
23. Castagno PL, Di Molfetta L, Merlo M, Barile G, Violato F, Buzzacchino A, et al. Prospects of prostanoid therapy. Minerva Cardioangiol 2000;48:1-10.
24. Rustin MHA, Kovacs IB, Cooke ED, Dowd PM, Bowcock Sa, Kirby JDT. Experience with PGE1 and PG12 infusions in patients with systemic sclerosis and Raynaud's phenomenon. Inter Angio J 1984;3:43-7.
25. Lamprecht P, Schnabel A, Gross WL. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon. Br J Rheumatol 1998;37:703-4.
26. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96:2782-4.
27. Angotti C, Matucci Cerinic M, Kalfin R, Generini S, Righi A, Conforti ML, et al. Prostaglandin E1 (PGE1) restores the levels of vWF and ACE and modulates the circulating levels of adhesion molecules in systemic sclerosis (SSc). Arthritis Rheum ;2000:43 (Suppl 9):S261.
28. Boyer-Neumann C, Brenot F, Wolf M, Peynaud-Debayle E, Duroux P, Meyer D, et al. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension. Thromb Haemostasis 1995;73:735-6.
29. Candela M, Iannino L, Pansoni A, Natalini M, Ravaglia F, Dalio L, et al. Hemocoagulative effects in patients with systemic sclerosis treated with Iloprost or Nifedipine. Eur J Clin Invest 1999;9(Suppl 1):83.
30. Bachmann F, Kruithof IEKO. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost 1984;10:6-17.
31. Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992;11:375-82.
32. Emeis JJ, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997;139:245-56.
33. Ridker PM. Hemostatic factors and the risk of myocardial infarction. N Engl J Med 1995;333:389-90.
34. Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular disease. Am J Clin Pathol 1994;10:109-13.
35. Soma Y, Takehara K, Sato S, Ishibashi Y. Increase in plasma thrombomodulin in patients with systemic sclerosis. J Rheumatol 1993;20:1444-5.
36. Mercié P, Seigneur M, Conri C. Plasma thrombomodulin as a marker of vascular damage in systemic sclerosis. J Rheumatol 1995;22:1440.
37. Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55:122-7.
38. Black CM, McWhirter A, Harrison NK, Kirk JM, Laurent GJ. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol 1989;28:98-103.